# Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

> **NCT03675282** · PHASE1,PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 82 (actual)

## Conditions studied

- Parkinson Disease
- REM Sleep Behavior Disorder
- Healthy

## Interventions

- **DRUG:** (11C)PE2I
- **DRUG:** Ioflupane

## Key facts

- **NCT ID:** NCT03675282
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-14
- **Primary completion:** 2024-04-23
- **Final completion:** 2024-04-23
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03675282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03675282, "Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03675282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*